Novel modulators of poly(ADP-ribose) polymerase

Trends in Pharmacological Sciences

Volumn 27, Issue 12, 2006, Pages 626-630

  Szabo, Csaba ^a   Pacher, Pal ^b   Swanson, Raymond A ^c  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CAFFEINE; COLECALCIFEROL; DOXYCYCLINE; ESTROGEN; MINOCYCLINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHOTRANSFERASE; PURINE; TETRACYCLINE DERIVATIVE; THEOPHYLLINE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CATALYSIS; CELL PROTECTION; DNA STRAND BREAKAGE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; STROKE;

ANIMALS; CEREBROVASCULAR ACCIDENT; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; POLY(ADP-RIBOSE) POLYMERASES; SEX FACTORS;

EID: 33750932728     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2006.10.003     Document Type: Article

References (57)

1. Virag L., and Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 54 (2002) 375-429
2. Jagtap P., and Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov. 4 (2005) 421-440
3. Graziani G., et al. PARP-1 inhibition to treat cancer, ischemia, inflammation. Pharmacol. Res. 52 (2005) 1-4
4. Szabo C., et al. DNA strand breakage, activation of poly(ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 1753-1758
5. Gilad E., et al. Protection by inhibition of poly(ADP-ribose) synthetase against oxidant injury in cardiac myoblasts in vitro. J. Mol. Cell. Cardiol. 29 (1997) 2585-2597
6. Garcia Soriano F., et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat. Med. 7 (2001) 108-113
7. Pacher P., et al. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51 (2002) 514-521
8. Du X., et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J. Clin. Invest. 112 (2003) 1049-1057
9. Pacher P., and Szabo C. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid. Redox Signal. 7 (2005) 1568-1580
10. 2+-dependent endonuclease in apoptosis and its inhibition by poly(ADP-ribose) polymerase. J. Biol. Chem. 275 (2000) 21302-21308
11. Szabo C., et al. Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation. Mol. Med. 10 (2004) 28-35
12. Pillai J.B., et al. Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy. Am. J. Physiol. Heart Circ. Physio. 291 (2006) H1545-H1553
13. 3, and ATP. Biochemistry 43 (2004) 210-216
14. Kauppinen T.M., et al. Direct phosphorylation and regulation of poly(ADP-ribose) polymerase-1 by extracellular signal-regulated kinases 1/2. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7136-7141
15. Alessandrini A., et al. MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 12866-12869
16. +-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell 119 (2004) 803-814
17. Veres B., et al. Decrease of the inflammatory response and induction of the Akt/protein kinase B pathway by poly-(ADP-ribose) polymerase 1 inhibitor in endotoxin-induced septic shock. Biochem. Pharmacol. 65 (2003) 1373-1382
18. Xu Y., et al. Poly(ADP-ribose) polymerase-1 signaling to mitochondria in necrotic cell death requires RIP1/TRAF2-mediated JNK1 activation. J. Biol. Chem. 281 (2006) 8788-8795
19. Midorikawa R., et al. KIF4 motor regulates activity-dependent neuronal survival by suppressing PARP-1 enzymatic activity. Cell 125 (2006) 371-383
20. Kolthur-Seetharam U., et al. Control of AIF-mediated cell death by the functional interplay of SIRT1 and PARP-1 in response to DNA damage. Cell Cycle 5 (2006) 873-877
21. Jackowski G., and Kun E. The effect of in vivo treatment with triiodothyronine on the in vitro synthesis of protein-poly(ADP)-ribose adducts by isolated cardiocyte nuclei and the separation of poly(ADP)-ribosylated proteins by phenol extraction and electrophoresis. J. Biol. Chem. 258 (1983) 12587-12593
22. Cesarone C.F., et al. Hepatic poly(ADP-ribose) polymerase activity in rat is controlled by thyroid hormones. Biochem. Biophys. Res. Commun. 203 (1994) 1548-1553
23. Giannoni P., et al. In vitro effect of 3,5,3′-triiodothyronine on poly(ADP-ribosyl)ation of DNA topoisomerase I. Ital. J. Biochem. 44 (1995) 129-136
24. Hagberg H., et al. PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. J. Neurochem. 90 (2004) 1068-1075
25. McCullough L.D., et al. Ischemic nitric oxide and poly(ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection. J. Cereb. Blood Flow Metab. 25 (2005) 502-512
26. Eliasson M.J., et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat. Med. 3 (1997) 1089-1095
27. Mabley J.G., et al. Gender differences in the endotoxin-induced inflammatory and vascular responses: potential role of poly(ADP-ribose) polymerase activation. J. Pharmacol. Exp. Ther. 315 (2005) 812-820
28. Hauser B., et al. The PARP-1 inhibitor ino-1001 facilitates hemodynamic stabilization without affecting DNA repair in porcine thoracic aortic cross-clamping-induced ischemia/reperfusion. Shock 25 (2006) 633-640
29. Kuohung W., et al. Tamoxifen, esterified estradiol, and physiologic concentrations of estradiol inhibit oxidation of low-density lipoprotein by endothelial cells. Am. J. Obstet. Gynecol. 184 (2001) 1060-1063
30. Suarez-Pinzon W.L., et al. Poly(ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes. Diabetes 52 (2003) 1683-1688
31. Shimoda K., et al. Effect of poly(ADP-ribose) synthetase inhibition on burn and smoke inhalation injury in sheep. Am. J. Physiol. Lung Cell. Mol. Physiol. 285 (2003) L240-L249
32. Mehilli J., et al. Gender and myocardial salvage after reperfusion treatment in acute myocardial infarction. J. Am. Coll. Cardiol. 45 (2005) 828-831
33. 3 is an inhibitor of poly(ADP)-ribose synthase. FASEB J. 17 (2003) 1123-1124
34. Yee Y.K., et al. Vitamin D receptor modulators for inflammation and cancer. Mini Rev. Med. Chem. 5 (2005) 761-778
35. Nagpal S., et al. Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev. 26 (2005) 662-687
36. Bauer P.I., et al. The influence of ATP on poly(ADP-ribose) metabolism. Int. J. Mol. Med. 16 (2005) 321-324
37. Virag L., and Szabo C. Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death. FASEB J. 15 (2001) 99-107
38. Geraets L., et al. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations. Biochem. Pharmacol. 72 (2006) 902-910
39. + depletion via PARP-1 inhibition in human pulmonary epithelial cells. Biochem. Biophys. Res. Commun. 338 (2005) 1805-1810
40. Tang-Liu D.D., et al. Disposition of caffeine and its metabolites in man. J. Pharmacol. Exp. Ther. 224 (1983) 180-185
41. Alano C.C., et al. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 9685-9690
42. Domercq M., and Matute C. Neuroprotection by tetracyclines. Trends Pharmacol. Sci. 25 (2004) 609-612
43. Elewa H.F., et al. Minocycline for short-term neuroprotection. Pharmacotherapy 26 (2006) 515-521
44. Tikka T., et al. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci. 21 (2001) 2580-2588
45. Morimoto N., et al. Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage. Brain Res. 1044 (2005) 8-15
46. Yrjanheikki J., et al. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 15769-15774
47. Yrjanheikki J., et al. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13496-13500
48. Fox C., et al. Minocycline confers early but transient protection in the immature brain following focal cerebral ischemia-reperfusion. J. Cereb. Blood Flow Metab. 25 (2005) 1138-1149
49. Du Y., et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14669-14674
50. Wu D.C., et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22 (2002) 1763-1771
51. Chen M., et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6 (2000) 797-801
52. Zhu S., et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417 (2002) 74-78
53. Kraus R.L., et al. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J. Neurochem. 94 (2005) 819-827
54. Peterson J.T. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail. Rev. 9 (2004) 63-79
55. Wang W., et al. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc. Res. 53 (2002) 165-174
56. Villarreal F.J., et al. Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation 108 (2003) 1487-1492
57. Graziani G., and Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol. Res. 52 (2005) 109-118